Spleen-Kidney Supplementing Formula Alleviates Renal Fibrosis in Diabetic Rats via TGF-β1-miR-21-PTEN Signaling Pathway

Figure 1

SKSF decreased FBG and HbA1c levels. (a) Fasting blood glucose, (b) HbA1c. Data were expressed as mean ± SD, n =10 rats per group. N, normal group; M, model group; Met, metformin group; SKSF-l, Spleen-Kidney Supplementing Formula group at a low dose; SKSF-m, Spleen-Kidney Supplementing Formula group at a medium dose; SKSF-h, Spleen-Kidney Supplementing Formula group at a high dose. <0.05 compared with model group.

(a)

(b)